Literature DB >> 16096414

The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Jonathan I Epstein1, William C Allsbrook, Mahul B Amin, Lars L Egevad.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 16096414     DOI： 10.1097/01.pas.0000173646.99337.b1

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN： 0147-5185            Impact factor:   6.394


× No keyword cloud information.
  721 in total

1.  Non-invasive quantification of tumor blood flow in prostate cancer using 15O-H2O PET/CT.

Authors:  Lars P Tolbod; Maria M Nielsen; Bodil G Pedersen; Søren Høyer; Hendrik J Harms; Michael Borre; Per Borghammer; Kirsten Bouchelouche; Jørgen Frøkiær; Jens Sørensen
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-10-20

2.  The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.

Authors:  Charles C Guo; Yan Wang; Li Xiao; Patricia Troncoso; Bogdan A Czerniak
Journal:  Hum Pathol       Date:  2011-09-19       Impact factor: 3.466

Review 3.  Histopathology reporting of prostate needle biopsies. 2005 update.

Authors:  Rodolfo Montironi; Remigio Vela Navarrete; Antonio Lopez-Beltran; Roberta Mazzucchelli; Gregor Mikuz; Aldo V Bono
Journal:  Virchows Arch       Date:  2006-04-22       Impact factor: 4.064

4.  Improving the reproducibility of the Gleason scores in small foci of prostate cancer--suggestion of diagnostic criteria for glandular fusion.

Authors:  B Helpap; G Kristiansen; M Beer; J Köllermann; U Oehler; A Pogrebniak; Ch Fellbaum
Journal:  Pathol Oncol Res       Date:  2011-12-17       Impact factor: 3.201

5.  Canadian Consensus Conference: The FDA decision on the use of 5ARIs.

Authors:  Laurence Klotz; Michael Chetner; Joseph Chin; Tony Finelli; Neil Fleshner; Yves Fradet; Larry Goldenberg; J Curtis Nickel; Robert Siemens; Alan So; Linda Sugar; Alexandre Zlotta; Eric Klein; Howard Parnes; David Penson
Journal:  Can Urol Assoc J       Date:  2012-04       Impact factor: 1.862

6.  Determination of adequate pelvic lymph node dissection range for Japanese males undergoing radical prostatectomy.

Authors:  Nobuki Furubayashi; Takahito Negishi; Hidenori Iwai; Kei Nagase; Kenichi Taguchi; Mototsugu Shimokawa; Motonobu Nakamura
Journal:  Mol Clin Oncol       Date:  2017-03-28

7.  The role of PSA density to predict a pathological tumour upgrade between needle biopsy and radical prostatectomy for low risk clinical prostate cancer in the modified Gleason system era.

Authors:  Stavros Sfoungaristos; Ioannis Katafigiotis; Petros Perimenis
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

8.  Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.

Authors:  Takuya Koie; Koji Mitsuzuka; Takahiro Yoneyama; Shintaro Narita; Sadafumi Kawamura; Yasuhiro Kaiho; Norihiko Tsuchiya; Tatsuo Tochigi; Tomonori Habuchi; Yoichi Arai; Chikara Ohyama; Tohru Yoneyama; Yuki Tobisawa
Journal:  Int J Clin Oncol       Date:  2014-04-29       Impact factor: 3.402

9.  Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence.

Authors:  Jason P Izard; Lawrence D True; Philip May; William J Ellis; Paul H Lange; Bruce Dalkin; Daniel W Lin; Rodney A Schmidt; Jonathan L Wright
Journal:  Am J Surg Pathol       Date:  2014-03       Impact factor: 6.394

10.  Expression of PARP-1 and its active polymer PAR in prostate cancer and benign prostatic hyperplasia in Chinese patients.

Authors:  Wenqi Wu; Hanliang Zhu; Yeping Liang; Zhenzhen Kong; Xiaolu Duan; Shujue Li; Zhijian Zhao; Dong Yang; Guohua Zeng
Journal:  Int Urol Nephrol       Date:  2014-01-17       Impact factor: 2.370
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.